DE69841806D1 - Ligandenbindungsstelle von rage und deren verwendungen - Google Patents
Ligandenbindungsstelle von rage und deren verwendungenInfo
- Publication number
- DE69841806D1 DE69841806D1 DE69841806T DE69841806T DE69841806D1 DE 69841806 D1 DE69841806 D1 DE 69841806D1 DE 69841806 T DE69841806 T DE 69841806T DE 69841806 T DE69841806 T DE 69841806T DE 69841806 D1 DE69841806 D1 DE 69841806D1
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- amino acid
- acid sequence
- present
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 9
- 102000005622 Receptor for Advanced Glycation End Products Human genes 0.000 abstract 6
- 108010045108 Receptor for Advanced Glycation End Products Proteins 0.000 abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 5
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000003993 interaction Effects 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/948,131 US6555651B2 (en) | 1997-10-09 | 1997-10-09 | Ligand binding site of rage and uses thereof |
PCT/US1998/021346 WO1999018987A1 (en) | 1997-10-09 | 1998-10-09 | Ligand binding site of rage and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69841806D1 true DE69841806D1 (de) | 2010-09-16 |
Family
ID=25487337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69841806T Expired - Lifetime DE69841806D1 (de) | 1997-10-09 | 1998-10-09 | Ligandenbindungsstelle von rage und deren verwendungen |
Country Status (12)
Country | Link |
---|---|
US (1) | US6555651B2 (ja) |
EP (2) | EP1023080B1 (ja) |
JP (2) | JP2001519401A (ja) |
AT (1) | ATE476192T1 (ja) |
AU (1) | AU9795898A (ja) |
CY (1) | CY1110884T1 (ja) |
DE (1) | DE69841806D1 (ja) |
DK (1) | DK1023080T3 (ja) |
ES (1) | ES2351876T3 (ja) |
HK (1) | HK1031100A1 (ja) |
PT (1) | PT1023080E (ja) |
WO (1) | WO1999018987A1 (ja) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6790443B2 (en) * | 1996-11-22 | 2004-09-14 | The Trustees Of Columbia University In The City Of New York | Method for treating symptoms of diabetes |
US7081241B1 (en) * | 1998-10-06 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Extracellular rage binding protein (EN-RAGE) and uses thereof |
US7258857B2 (en) * | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
US7101838B2 (en) * | 1997-08-05 | 2006-09-05 | The Trustees Of Columbia University In The City Of New York | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts |
US6465422B1 (en) * | 1998-04-17 | 2002-10-15 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting tumor invasion or spreading in a subject |
JP2002526117A (ja) * | 1998-10-06 | 2002-08-20 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | 細胞外新規rage結合タンパク質(en−rage)及びその使用 |
JP2003507013A (ja) * | 1999-08-13 | 2003-02-25 | ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク | βシートフィブリルのRAGEへの結合を阻害する方法及びその結果 |
US20050170382A1 (en) * | 1999-10-06 | 2005-08-04 | The Trustees Of Columbia University In The City Of New York. | RAGE-related compositions |
US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
US6613801B2 (en) | 2000-05-30 | 2003-09-02 | Transtech Pharma, Inc. | Method for the synthesis of compounds of formula I and their uses thereof |
EP1724589A3 (en) * | 2000-05-30 | 2007-04-25 | TransTech Pharma Inc. | Methods to identify compounds that modulate rage |
US7919670B1 (en) | 2000-08-14 | 2011-04-05 | The Trustees Of Columbia University In The City Of New York | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof |
PE20020394A1 (es) | 2000-08-18 | 2002-06-21 | Agouron Pharma | Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2 |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
AU2002213192A1 (en) * | 2000-10-13 | 2002-04-22 | The Trustees Of Columbia University In The City Of New York | A method for inhibiting new tissue growth in blood vessels in a patient subjected to blood vessel injury |
WO2002070473A2 (en) | 2001-03-05 | 2002-09-12 | Transtech Pharma, Inc. | Carboxamide derivatives as therapeutic agents |
WO2002069965A1 (en) | 2001-03-05 | 2002-09-12 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
CN100525763C (zh) | 2002-03-05 | 2009-08-12 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
CN1774445A (zh) * | 2002-08-16 | 2006-05-17 | 惠氏公司 | 用于治疗rage相关病症的组合物和方法 |
US8067371B2 (en) * | 2003-05-09 | 2011-11-29 | The Trustees Of Columbia University In The City Of New York | RAGE G82S-related methods and compositions for treating inflammatory disorders |
US7470521B2 (en) * | 2004-07-20 | 2008-12-30 | Critical Therapeutics, Inc. | RAGE protein derivatives |
EP1781700B1 (en) | 2004-08-03 | 2014-03-19 | TransTech Pharma, LLC | Rage fusion proteins and methods of use |
KR20070057818A (ko) * | 2004-08-03 | 2007-06-07 | 트랜스테크 파르마, 인크. | Rage 융합 단백질 및 이의 사용 방법 |
US20060205669A1 (en) * | 2004-09-16 | 2006-09-14 | The Regents Of The University Of California | G-type peptides and other agents to ameliorate atherosclerosis and other pathologies |
CA2581505A1 (en) * | 2004-09-27 | 2006-04-06 | Centocor, Inc. | Srage mimetibody, compositions, methods and uses |
AU2005314043A1 (en) | 2004-12-06 | 2006-06-15 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
JP2008526243A (ja) * | 2005-01-18 | 2008-07-24 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Agerペプチド及びその使用 |
US9291621B2 (en) * | 2005-01-18 | 2016-03-22 | AbbVie Deutschland GmbH & Co. KG | AGER-peptides and use thereof |
WO2006099620A2 (en) * | 2005-03-17 | 2006-09-21 | The Trustees Of Columbia University In The City Of New York | Rage/diaphanous interaction and related compositions and methods |
AU2006242651B2 (en) * | 2005-04-29 | 2013-05-16 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US20080207499A1 (en) * | 2005-06-29 | 2008-08-28 | Gaetano Barile | Rage-related methods for treating and preventing diabetic retinopathy |
ES2431632T3 (es) * | 2005-12-23 | 2013-11-27 | Gcoder Systems Ab | Patrón de posicionamiento |
US20090004190A1 (en) * | 2006-02-09 | 2009-01-01 | Mjalli Adnan M M | Rage Fusion Proteins And Methods Of Use |
EP2380983A3 (en) * | 2006-05-05 | 2012-12-05 | TransTech Pharma Inc. | RAGE fusion proteins, formulations, and methods of use thereof |
WO2008100470A2 (en) * | 2007-02-15 | 2008-08-21 | Transtech Pharma, Inc. | Rage - immunoglobulin fusion proteins |
WO2008153957A1 (en) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Uses of rage antagonists for treating obesity and related diseases |
JP5706688B2 (ja) | 2007-06-14 | 2015-04-22 | ギャラクティカ ファーマシューティカルズ, インク. | Rage融合タンパク質 |
US8557767B2 (en) | 2007-08-28 | 2013-10-15 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
AU2008296478B9 (en) | 2007-08-28 | 2015-03-19 | The Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
WO2010122460A1 (en) | 2009-04-20 | 2010-10-28 | Pfizer Inc. | Control of protein glycosylation and compositions and methods relating thereto |
WO2011041198A1 (en) | 2009-09-30 | 2011-04-07 | Transtech Pharma, Inc. | Substituted imidazole derivatives for treatment of alzheimers disease |
JP5894540B2 (ja) | 2010-02-18 | 2016-03-30 | ブイティーブイ・セラピューティクス・エルエルシー | フェニル−ヘテロアリール誘導体とその使用の方法 |
JP5999542B2 (ja) * | 2010-11-18 | 2016-09-28 | 国立研究開発法人農業・食品産業技術総合研究機構 | リガンド様活性を有する分子の検出方法 |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9717710B2 (en) | 2012-10-05 | 2017-08-01 | Vtv Therapeutics Llc | Treatment of mild and moderate Alzheimer's disease |
KR101595630B1 (ko) * | 2013-01-18 | 2016-02-18 | 성균관대학교산학협력단 | Rage 단백질-베타아밀로이드 상호작용 억제제, 및 이를 유효성분으로 함유하는 베타아밀로이드 집적 관련 질환의 예방 또는 치료용 약학적 조성물 |
US10653747B2 (en) | 2014-07-31 | 2020-05-19 | Uab Research Foundation | ApoE mimetic peptides and higher potency to clear plasma cholesterol |
WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
WO2019190823A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
EP3864008A1 (en) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
CA2182731A1 (en) | 1994-02-03 | 1995-08-10 | Michael P. Vitek | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
US6184205B1 (en) * | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
EP0870040A2 (en) * | 1995-12-29 | 1998-10-14 | Chiron Corporation | Gene delivery vehicle-targeting ligands |
WO1997026913A1 (en) | 1996-01-26 | 1997-07-31 | The Trustees Of Columbia University In The City Of New York | A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE |
CN1229498C (zh) * | 1996-02-21 | 2005-11-30 | 美国国有卫生与人类服务部 | 重组的核糖核酸酶蛋白质 |
AU2696097A (en) | 1996-04-16 | 1997-11-07 | Schering Aktiengesellschaft | Advanced glycosylation end-product receptor peptides and uses therefor |
US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US5688653A (en) | 1996-06-27 | 1997-11-18 | The Picower Institute For Medical Research | 3-alkylamino-2-hydroxy-4-hydroxymethyl-2-cyclopenten-1-one advanced glycosylation endproducts and methods of use therefor |
US6555651B2 (en) * | 1997-10-09 | 2003-04-29 | The Trustees Of Columbia University In The City Of New York | Ligand binding site of rage and uses thereof |
-
1997
- 1997-10-09 US US08/948,131 patent/US6555651B2/en not_active Expired - Fee Related
-
1998
- 1998-10-09 EP EP98952204A patent/EP1023080B1/en not_active Expired - Lifetime
- 1998-10-09 DE DE69841806T patent/DE69841806D1/de not_active Expired - Lifetime
- 1998-10-09 PT PT98952204T patent/PT1023080E/pt unknown
- 1998-10-09 JP JP2000515619A patent/JP2001519401A/ja not_active Withdrawn
- 1998-10-09 AT AT98952204T patent/ATE476192T1/de active
- 1998-10-09 WO PCT/US1998/021346 patent/WO1999018987A1/en active Application Filing
- 1998-10-09 EP EP10171799A patent/EP2343316A1/en not_active Withdrawn
- 1998-10-09 AU AU97958/98A patent/AU9795898A/en not_active Abandoned
- 1998-10-09 DK DK98952204.0T patent/DK1023080T3/da active
- 1998-10-09 ES ES98952204T patent/ES2351876T3/es not_active Expired - Lifetime
-
2001
- 2001-02-02 HK HK01100756.3A patent/HK1031100A1/xx not_active IP Right Cessation
-
2010
- 2010-01-08 JP JP2010002870A patent/JP2010143932A/ja active Pending
- 2010-11-04 CY CY20101100995T patent/CY1110884T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1023080B1 (en) | 2010-08-04 |
ES2351876T3 (es) | 2011-02-11 |
ATE476192T1 (de) | 2010-08-15 |
EP1023080A1 (en) | 2000-08-02 |
PT1023080E (pt) | 2010-10-18 |
JP2001519401A (ja) | 2001-10-23 |
US6555651B2 (en) | 2003-04-29 |
AU9795898A (en) | 1999-05-03 |
US20010053357A1 (en) | 2001-12-20 |
WO1999018987A1 (en) | 1999-04-22 |
CY1110884T1 (el) | 2015-06-10 |
JP2010143932A (ja) | 2010-07-01 |
EP2343316A1 (en) | 2011-07-13 |
EP1023080A4 (en) | 2003-03-19 |
HK1031100A1 (en) | 2001-06-01 |
DK1023080T3 (da) | 2010-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69841806D1 (de) | Ligandenbindungsstelle von rage und deren verwendungen | |
DK1482042T3 (da) | Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren | |
RU95110871A (ru) | Способы определения нуклеотидной последовательности | |
ES2162132T3 (es) | Polimerasa de adn termoestable procedente de thermoanaerobacter thermohydrosulfuricus y enzimas mutantes, de actividad exonucleasa suprimida asi obtenidos. | |
GB9720054D0 (en) | Biological products | |
PL335140A1 (en) | Therapeutic agent for treating lymphatic system carcinomas | |
WO1996009386A3 (en) | Allelic variation of the serotonin 5ht2c receptor | |
DK0495918T3 (da) | Aminosyre-beta-lyaseenzyminhibitorer som deodoranter | |
MEYER et al. | ADP-ribosyl proteins formed by pertussis toxin are specifically cleaved by mercury ions | |
ATE534742T1 (de) | Polypeptide und nukleinsäuren von phorphorymonas gingivalis | |
DE69927795D1 (en) | Temperaturstabile dna polymerase aus thermoanaerobacter thermohydrosulfuricus | |
NO972313D0 (no) | Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav | |
AU8811298A (en) | Novel peptides and polypeptides useful for regenerating the nervous system | |
ATE315577T1 (de) | Neue aminosäuresequenzen, deren kodierende dns, antikörper dagegen und deren verwendungen | |
CO4480058A1 (es) | Genes codificantes y procedimiento de expresion de una nueva enzima: ftalil amidasa | |
NZ296765A (en) | 8-cyclohexyl substituted xanthine derivatives and medicaments | |
DE59105231D1 (de) | Klonierung und Überexpression von Glucose-6-Phosphat-Dehydrogenase aus Leuconostoc dextranicus. | |
GB2262528B (en) | Further improvements relating to the radiolabelling of proteins | |
EP0837074A3 (en) | Biologically active fibronectin fragment as cancer metastasis inhibitor | |
EP1013665A4 (en) | NEW POLYPEPTIDE DEPLOYING WATER CIRCULATION ACTIVITY AND DNA SEQUENCE | |
EP0911408A3 (en) | DNA coding for serine/threonine kinase | |
WO2001049714A3 (en) | Nope polypeptides, encoding nucleic acids and methods of use | |
CA2177600A1 (fr) | Sequences d'acides nucleiques regulatrices et utilisations | |
Linder et al. | Separation of human pancreatic carboxypeptidase A isoenzymes by high performance liquid chromatography | |
Jonák et al. | Characterization of Elongation Factor Tu from Bacillus Subtilis Modified by Affinity Labelling |